USP8 and neoplasm: Analysis of infiltrated immune cells demonstrated that the USP8 inhibitor combined with anti-PD-L1 treatment could significantly increase the percentage of CD8+ T cells, but not the CD4+ cells in tumor-infiltrating lymphocytes (TILs) (Fig. 6h and Supplementary Fig. 6f).